{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:45:25Z","timestamp":1783608325796,"version":"3.55.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Chronic pain and functional impairment interfere with the quality of life of subjects suffering from temporomandibular joint (TMJ) disorders. Intra-articular (IA) hyaluronic acid (HA) injections have been shown to alleviate pain and improve mandibular mobility in patients with TMJ osteoarthritis (OA).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>The primary aim of the study was to identify the prognostic factors of patient satisfaction for a single IA injection of a mannitol-modified crosslinked HA (HANOX-M-XL) in patients with TMJ-OA. The second goal was to obtain clinical data on effectiveness, safety and mandibular mobility throughout a six-month follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and methods<\/jats:title>\n                <jats:p>This was an observational single-arm prospective trial with a six-month follow-up. Inclusion criteria: patients with TMJ-OA which is not relieved by analgesics and\/or non-steroidal-anti-inflammatory drugs and\/or orthotics, with radiological evidence of TMJ-OA. All patients received a single IA injection of 1\u2009ml HANOX-M-XL in the target TMJ. The primary endpoint was patient satisfaction on day 180. The main secondary outcome measures were pain variation on a 11-point numeric scale (0\u201311) between the date of injection and month six, the variation over time of the Maximum Inter-Incisal Opening Distance (MIIOD) and the patient\u2019s assessment of effectiveness. Predictive factors of success or failure were also studied. All adverse events were recorded.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>36 subjects (mean age 55.3\u2009years, mean disease duration 98\u2009months), covering a total of 52 injected TMJs, were included. Between baseline and endpoint, the average pain while chewing decreased dramatically from 6.9\u2009\u00b1\u20091.2 to 2.9\u2009\u00b1\u20091.3 (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and the MIIOD increased from 29\u2009\u00b1\u20097 to 35\u2009\u00b1\u20095\u2009mm (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). On day 180, all patients were satisfied with the treatment, with 34 patients (94%) rating it as highly effective or effective. Tolerability was good in all but one patient. In the multivariate analysis, patient satisfaction on day 180 was highly correlated with the pain while chewing score, pain on palpation score and the decrease of pain over time (all <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) but not with MIIOD, gender, age, bruxism, articular noise and symptom duration. Previous viscosupplementation was also related to higher satisfaction (<jats:italic>p<\/jats:italic>\u2009=\u20090.01).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Despite a long history of pain, most of the patients with symptomatic TMJ-OA benefited from a single injection of HANOX-M-XL, as shown by the sustained (up to 6 months) decrease in pain and improvement in mandibular mobility, with no safety concerns.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12891-022-05352-3","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T09:03:10Z","timestamp":1651050190000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Predictors for patient satisfaction of a single intra-articular injection of crosslinked hyaluronic acid combined with mannitol (HANOX-M-XL) in patients with temporomandibular joint osteoarthritis. Results of a prospective open-label pilot study (HAPPYMINI-ARTEMIS trial)"],"prefix":"10.1186","volume":"23","author":[{"given":"Dominique","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Baron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Baerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Bodere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Conrozier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"5352_CR1","doi-asserted-by":"publisher","first-page":"5793","DOI":"10.12659\/MSM.908821","volume":"24","author":"H Sun","year":"2018","unstructured":"Sun H, Su Y, Song N, Li C, Shi Z, Li L. Clinical outcome of sodium hyaluronate injection into the superior and inferior joint space for osteoarthritis of the temporomandibular joint evaluated by cone-beam computed tomography: a retrospective study of 51 patients and 56 joints. Med Sci Monit. 2018;24:5793\u2013801. https:\/\/doi.org\/10.12659\/MSM.908821.","journal-title":"Med Sci Monit"},{"issue":"2","key":"5352_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3390\/ijms20020277","volume":"20","author":"F Zotti","year":"2019","unstructured":"Zotti F, Albanese M, Rodella LF, Nocini PF. Platelet-rich plasma in treatment of temporomandibular joint dysfunctions: narrative review. Int J Mol Sci. 2019;20(2):277. https:\/\/doi.org\/10.3390\/ijms20020277.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"5352_CR3","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1053\/joms.2001.25015","volume":"59","author":"N Ta\u015fkaya-Yilmaz","year":"2001","unstructured":"Ta\u015fkaya-Yilmaz N, O\u011f\u00fctcen-Toller M. Magnetic resonance imaging evaluation of temporomandibular joint disc deformities in relation to type of disc displacement. J Oral Maxillofac Surg. 2001;59(8):860\u20135; discussion 865-6. https:\/\/doi.org\/10.1053\/joms.2001.25015.","journal-title":"J Oral Maxillofac Surg"},{"issue":"3","key":"5352_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1179\/crn.2010.023","volume":"28","author":"D Manfredini","year":"2010","unstructured":"Manfredini D, Piccotti F, Guarda-Nardini L. Hyaluronic acid in the treatment of TMJ disorders: a systematic review of the literature. Cranio. 2010;28(3):166\u201376. https:\/\/doi.org\/10.1179\/crn.2010.023.","journal-title":"Cranio"},{"issue":"2","key":"5352_CR5","doi-asserted-by":"publisher","first-page":"80","DOI":"10.3109\/00016350903431118","volume":"68","author":"L Dahlstr\u00f6m","year":"2010","unstructured":"Dahlstr\u00f6m L, Carlsson GE. Temporomandibular disorders and oral health-related quality of life. A systematic review. Acta Odontol Scand. 2010;68(2):80\u20135. https:\/\/doi.org\/10.3109\/00016350903431118.","journal-title":"Acta Odontol Scand"},{"issue":"4","key":"5352_CR6","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.0904-2512.2004.00024.x","volume":"33","author":"T Takahashi","year":"2004","unstructured":"Takahashi T, Tominaga K, Takano H, Ariyoshi W, Habu M, Fukuda J, et al. A decrease in the molecular weight of hyaluronic acid in synovial fluid from patients with temporomandibular disorders. J Oral Pathol Med. 2004;33(4):224\u20139. https:\/\/doi.org\/10.1111\/j.0904-2512.2004.00024.x.","journal-title":"J Oral Pathol Med"},{"issue":"6","key":"5352_CR7","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1097\/SCS.0b013e3182a30566","volume":"24","author":"K Triantaffilidou","year":"2013","unstructured":"Triantaffilidou K, Venetis G, Bika O. Efficacy of hyaluronic acid injections in patients with osteoarthritis of the temporomandibular joint. A comparative study. J Craniofac Surg. 2013;24(6):2006\u20139. https:\/\/doi.org\/10.1097\/SCS.0b013e3182a30566.","journal-title":"J Craniofac Surg"},{"issue":"6","key":"5352_CR8","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0278-2391(85)80050-1","volume":"43","author":"S Kopp","year":"1985","unstructured":"Kopp S, Wenneberg B, Haraldson T, Carlsson GE. The short-term effect of intra-articular injections of sodium hyaluronate and corticosteroid on temporomandibular joint pain and dysfunction. J Oral Maxillofac Surg. 1985;43(6):429\u201335. https:\/\/doi.org\/10.1016\/s0278-2391(85)80050-1.","journal-title":"J Oral Maxillofac Surg"},{"issue":"11","key":"5352_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1016\/0278-2391(87)90443-5","volume":"45","author":"S Kopp","year":"1987","unstructured":"Kopp S, Carlsson GE, Haraldson T, Wenneberg B. Long-term effect of intra-articular injections of sodium hyaluronate and corticosteroid on temporomandibular joint arthritis. J Oral Maxillofac Surg. 1987;45(11):929\u201335. https:\/\/doi.org\/10.1016\/0278-2391(87)90443-5.","journal-title":"J Oral Maxillofac Surg"},{"issue":"4","key":"5352_CR10","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.revsto.2016.07.020","volume":"117","author":"P Marty","year":"2016","unstructured":"Marty P, Louvrier A, Weber E, Dubreuil PA, Chatelain B, Meyer C. Arthrocent\u00e8se de l\u2019articulation temporomandibulaire et injection(s) intra-articulaire(s) : un \u00e9tat des lieux [Arthrocentesis of the temporomandibular joint and intra-articular injections : an update]. Rev Stomatol Chir Maxillofac Chir Orale. 2016;117(4):266\u201372. https:\/\/doi.org\/10.1016\/j.revsto.2016.07.020.","journal-title":"Rev Stomatol Chir Maxillofac Chir Orale"},{"issue":"11","key":"5352_CR11","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1016\/j.joms.2012.07.020","volume":"70","author":"L Guarda-Nardini","year":"2012","unstructured":"Guarda-Nardini L, Cadorin C, Frizziero A, Ferronato G, Manfredini D. Comparison of 2 hyaluronic acid drugs for the treatment of temporomandibular joint osteoarthritis. J Oral Maxillofac Surg. 2012;70(11):2522\u201330. https:\/\/doi.org\/10.1016\/j.joms.2012.07.020.","journal-title":"J Oral Maxillofac Surg"},{"issue":"5","key":"5352_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00405-002-0456-z","volume":"259","author":"L Guarda-Nardini","year":"2002","unstructured":"Guarda-Nardini L, Tito R, Staffieri A, Beltrame A. Treatment of patients with arthrosis of the temporomandibular joint by infiltration of sodium hyaluronate: a preliminary study. Eur Arch Otorhinolaryngol. 2002;259(5):279\u201384. https:\/\/doi.org\/10.1007\/s00405-002-0456-z.","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"6","key":"5352_CR13","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1053\/joms.2001.23368","volume":"59","author":"GH Alpaslan","year":"2001","unstructured":"Alpaslan GH, Alpaslan C. Efficacy of temporomandibular joint arthrocentesis with and without injection of sodium hyaluronate in treatment of internal derangements. J Oral Maxillofac Surg. 2001;59(6):613\u20138; discussion 618-9. https:\/\/doi.org\/10.1053\/joms.2001.23368.","journal-title":"J Oral Maxillofac Surg"},{"issue":"1","key":"5352_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s12891-017-1585-2","volume":"18","author":"Y Henrotin","year":"2017","unstructured":"Henrotin Y, Berenbaum F, Chevalier X, Marty M, Richette P, Rannou F. Reduction of the serum levels of a specific biomarker of cartilage degradation (Coll2-1) by hyaluronic acid (KARTILAGE\u00ae CROSS) compared to placebo in painful knee osteoarthritis patients: the EPIKART study, a pilot prospective comparative randomized double blind trial. BMC Musculoskelet Disord. 2017;18(1):222. https:\/\/doi.org\/10.1186\/s12891-017-1585-2.","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"5352_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12891-016-1359-2","volume":"18","author":"F Eymard","year":"2017","unstructured":"Eymard F, Maillet B, Lellouche H, Mellac-Ducamp S, Brocq O, Loeuille D, et al. Osteoarthritis Group of the French Society of rheumatology and of the French research Group in Interventional Rheumatology. Predictors of response to viscosupplementation in patients with hip osteoarthritis: results of a prospective, observational, multicentre, open-label, pilot study. BMC Musculoskelet Disord. 2017;18(1):3. https:\/\/doi.org\/10.1186\/s12891-016-1359-2.","journal-title":"BMC Musculoskelet Disord"},{"key":"5352_CR16","doi-asserted-by":"publisher","unstructured":"Dauvissat J, Rizzo C, Lellouche H, Porterie J, Melac-Ducamp S, Locquet V, et al. Safety and predictive factors of short-term efficacy of a single injection of mannitol-modified Cross-linked hyaluronic acid in patients with Trapeziometacarpal osteoarthritis. Results of a multicentre prospective open-label pilot study (INSTINCT trial). Clin Med Insights Arthritis Musculoskelet Disord. 2018:11:1179544118782901. https:\/\/doi.org\/10.1177\/1179544118782901.","DOI":"10.1177\/1179544118782901"},{"issue":"5","key":"5352_CR17","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1111\/j.1365-2842.2010.02164.x","volume":"38","author":"L Guarda-Nardini","year":"2011","unstructured":"Guarda-Nardini L, Ferronato G, Favero L, Manfredini D. Predictive factors of hyaluronic acid injections short-term effectiveness for TMJ degenerative joint disease. J Oral Rehabil. 2011;38(5):315\u201320. https:\/\/doi.org\/10.1111\/j.1365-2842.2010.02164.x.","journal-title":"J Oral Rehabil"},{"issue":"7","key":"5352_CR18","doi-asserted-by":"publisher","first-page":"701","DOI":"10.3390\/polym10070701","volume":"10","author":"A Fallacara","year":"2018","unstructured":"Fallacara A, Baldini E, Manfredini S, Vertuani S. Hyaluronic acid in the third millennium. Polymers (Basel). 2018;10(7):701. https:\/\/doi.org\/10.3390\/polym10070701.","journal-title":"Polymers (Basel)"},{"issue":"1","key":"5352_CR19","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40744-014-0001-8","volume":"1","author":"T Conrozier","year":"2014","unstructured":"Conrozier T, Mathieu P, Rinaudo M. Mannitol preserves the viscoelastic properties of hyaluronic acid in an in vitro model of oxidative stress. Rheumatol Ther. 2014;1(1):45\u201354. https:\/\/doi.org\/10.1007\/s40744-014-0001-8.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"5352_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.11607\/jop.1151","volume":"28","author":"E Schiffman","year":"2014","unstructured":"Schiffman E, Ohrbach R, Truelove E, Look J, Anderson G, Goulet JP, et al. International RDC\/TMD consortium network, international association for dental research; orofacial pain special interest group, International Association for the Study of Pain. Diagnostic criteria for temporomandibular disorders (DC\/TMD) for clinical and research applications: recommendations of the international RDC\/TMD consortium network* and orofacial pain special interest group\u2020. J Oral Facial Pain Headache. 2014;28(1):6\u201327. https:\/\/doi.org\/10.11607\/jop.1151.","journal-title":"J Oral Facial Pain Headache"},{"issue":"3","key":"5352_CR21","doi-asserted-by":"publisher","first-page":"226","DOI":"10.2174\/1573397113666170710115558","volume":"14","author":"T Conrozier","year":"2018","unstructured":"Conrozier T. Is the addition of a polyol to hyaluronic acid a significant advance in the treatment of osteoarthritis? Curr Rheumatol Rev. 2018;14(3):226\u201330. https:\/\/doi.org\/10.2174\/1573397113666170710115558.","journal-title":"Curr Rheumatol Rev"},{"issue":"1","key":"5352_CR22","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12891-021-04089-9","volume":"22","author":"JK Park","year":"2021","unstructured":"Park JK, Ahn SH, Shin K, Lee YJ, Song YW, Lee EB. Predictors of a placebo response in patients with hand osteoarthritis: post-hoc analysis of two randomized controlled trials. BMC Musculoskelet Disord. 2021;22(1):244. https:\/\/doi.org\/10.1186\/s12891-021-04089-9.","journal-title":"BMC Musculoskelet Disord"},{"issue":"10","key":"5352_CR23","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.joca.2017.07.006","volume":"25","author":"Y Yazici","year":"2017","unstructured":"Yazici Y, McAlindon TE, Fleischmann R, Gibofsky A, Lane NE, Kivitz AJ, et al. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study. Osteoarthr Cartil. 2017;25(10):1598\u2013606. https:\/\/doi.org\/10.1016\/j.joca.2017.07.006.","journal-title":"Osteoarthr Cartil"},{"issue":"5","key":"5352_CR24","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.joca.2004.02.001","volume":"12","author":"T Pham","year":"2004","unstructured":"Pham T, van der Heijde D, Altman RD, Anderson JJ, Bellamy N, Hochberg M, et al. OMERACT-OARSI initiative: osteoarthritis research society international set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthr Cartil. 2004;12(5):389\u201399. https:\/\/doi.org\/10.1016\/j.joca.2004.02.001.","journal-title":"Osteoarthr Cartil"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05352-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-022-05352-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-022-05352-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T09:09:22Z","timestamp":1651050562000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmusculoskeletdisord.biomedcentral.com\/articles\/10.1186\/s12891-022-05352-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["5352"],"URL":"https:\/\/doi.org\/10.1186\/s12891-022-05352-3","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ARTEMIS study was performed in accordance with appropriate guidelines. The patient informed consent form and the protocol that complied with the requirements of the International Conference on Harmonization (ICH) were reviewed and approved by the CCTIRS. The study was registered on August 13, 2018 under ClinicalTrials.gov Identifier NCT03627429.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"D. Baron received fees from LABRHA for board member services and from LCA and Expansciences for speaker services.H. Baron does not declare any conflicts of interest.C. Baraer does not declare any conflicts of interest.C. Bod\u00e9r\u00e9 does not declare any conflicts of interest.T. Conrozier received fees from LABRHA, SANOFI, MEDAC and FIDIA for scientific, speaker and\/or board member services.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}